Apadamtase Alfa

Summary

Apadamtase Alfa (CHEMBL4594607) is an approved enzyme; indicated across 3 conditions including thrombotic thrombocytopenic purpura and sickle cell disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• Indications: 3 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594607
Name	Apadamtase Alfa
Type	Enzyme
Max phase	4

Also known as: Adamts13 q23, recombinant, recombinant human, Adamts13, Adzynma, Apadamtasa alfa, Apadamtase alfa, BAX 930, BAX-930, Bax930, Native radamts13 q23, RADAMTS-13

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
thrombotic thrombocytopenic purpura	4	MONDO:0018896	MONDO:0019740

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
sickle cell disease	1	MONDO:0011382	MONDO:0011382

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04683003	PHASE3	ACTIVE_NOT_RECRUITING	A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT03393975	PHASE3	COMPLETED	A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
NCT07392450	PHASE2	RECRUITING	A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT03922308	PHASE2	COMPLETED	Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT05714969	PHASE2	COMPLETED	A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
NCT03997760	PHASE1	COMPLETED	A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
NCT05770219	Not specified	APPROVED_FOR_MARKETING	Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).